Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + inituzumab + pyrotinib for previously treated HER2-positive advanced breast cancer
ChiCTR2600121825Phase 2Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin, inetetamab and pyrotinib in breast cancer, sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: objective response rate. Started Apr 2026; status: recruiting.
02
Drugs
eribulininetetamabpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600121825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121825.